Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

BACKGROUND: Tiotropium is reimbursed since March 2004 in Belgium for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Questions however remain on this product's value for money. The purpose of this study is to calculate tiotropium's cost-effectiveness under real-world conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Neyt, Mattias, Devriese, Stephan, Thiry, Nancy, Van den Bruel, Ann
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954895/
https://www.ncbi.nlm.nih.gov/pubmed/20843311
http://dx.doi.org/10.1186/1471-2466-10-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2954895/
https://www.ncbi.nlm.nih.gov/pubmed/20843311
http://dx.doi.org/10.1186/1471-2466-10-47

Ejemplares similares